- Case report
- Open Access
- Open Peer Review
Infective endocarditis following tumor necrosis factor-α antagonist therapy for management of psoriatic erythroderma: a case report
© The Author(s). 2017
- Received: 19 March 2016
- Accepted: 2 November 2016
- Published: 9 February 2017
The introduction of biological agents, such as infliximab, which act against tumor necrosis factor-α was a major advance for the treatment of an increasing number of chronic diseases. Tumor necrosis factor-α antagonists represent a major therapeutic advance for the management of chronic inflammatory diseases, such as psoriasis. Previous studies have reported that the use of tumor necrosis factor-α antagonists increased the risk of opportunistic infections and reactivation of latent bacterial infections. Cardiac involvement, such as infective endocarditis, is very rare in the literature.
A 77-year-old Asian man with a 10-year history of psoriatic erythroderma was referred due to high fever and general malaise. He was treated with Predonine (prednisolone) and infliximab. After treatment, cardiac echography showed mitral valve vegetation and brain magnetic resonance imaging indicated multiple fresh infarctions. He died from large brain infarction in October 2013. An autopsy showed fresh thrombosis in his left middle cerebral artery, mitral valve vegetations, and septic micro-embolisms in multiple organs.
Lethal bacterial endocarditis was revealed after administration of tumor necrosis factor-α inhibitor, infliximab, for the treatment of psoriatic erythroderma. An autopsy showed vegetation in his mitral valve and brain infarction with fresh purulent embolism in his left middle cerebral artery and septic micro-embolisms.
- TNF-α antagonist
- Psoriasis erythroderma
- Bacterial endocarditis
The introduction of biological agents, such as infliximab, which act against tumor necrosis factor-α (TNF-α) was a major advance for the treatment of an increasing number of chronic diseases. TNF-α antagonists represent a major therapeutic advance for the management of chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis . Due to their inhibition of proinflammatory cytokines, their use has been associated with an increased risk of severe infection . Previous studies have reported an increased risk of opportunistic infections and reactivation of latent bacterial infections . Although some studies concluded an increased risk of infection in patients receiving infliximab , the relative risk for patients receiving TNF-α inhibitors was reported to be up to twice that of control , and even higher at the treatment’s onset. Cardiac involvement, such as infective endocarditis, is very rare in the literature [6, 7].
We report the case of a man with infective endocarditis due to the TNF-α inhibitor, infliximab, for the management of psoriatic erythroderma.
Three days later, he presented with shortness of breathing, general malaise, and anorexia. He was referred to our department of cardiovascular medicine in September 2013. His past medical history showed that he had herpes zoster 6 months earlier. His social history was not significant for alcoholic drinks or tobacco smoking. He denied illicit drug use. His job was a farmer. No particular environment was evident.
We described a patient with lethal bacterial endocarditis after administration of TNF-α inhibitor, infliximab, for the treatment of psoriatic erythroderma. An autopsy showed vegetation in his mitral valve and brain infarction with fresh purulent embolism in his left middle cerebral artery and septic micro-embolisms.
Erythrodermic psoriasis is a severe variant of psoriasis with a reported prevalence among patients with psoriasis ranging from 1.5 to 31 % . Left untreated, it may lead to serious morbidity and even mortality. Erythrodermic psoriasis is often difficult to manage, and the therapies that are currently available may prove to be unsatisfactory. Biological agents offer a new alternative therapeutic approach , although there are no controlled trials to support their use, particularly as a long-term therapy option. The relation between erythrodermic psoriasis and cardiac disease is only mentioned in coronary artery disease. In many ways, psoriasis can be considered a model autoimmune disease . The most common causes of death in patients with erythroderma are pneumonia, septicemia, and heart failure. Older patients who develop complications such as infection, fluid/electrolyte imbalances, and cardiac failure are at higher risk of mortality . In our case, septic organ failure due to treatment-induced bacterial endocarditis was the cause of death.
Bacteremia due to receiving TNF-α inhibitors was reported . The national registries suggest a small but significantly increased incidence of serious infection ranging from 1.2 to 2.78 times that of controls treated with methotrexate . Mycobacteria, Staphylococcus aureus, Listeria monocytogenes, varicella zoster virus, and Leishmania species repeatedly appear in the case report literature and should be in the mind of the clinician faced with a serious infection in a patient with an unknown pathogen who is being treated with etanercept, infliximab, or adalimumab . Staphylococcus aureus represented the most frequent causative pathogen and was mostly associated with bones and/or joints infections and with a worse outcome compared to that observed with other bacterial pathogens. Bacterial infections seem to occur early, within the first 6 months after the initiation of TNF-α inhibitor therapies [12, 13]. There is no evidence for an increased rate of staphylococcal carriage among anti- TNF-α treated patients .
TNF-α inhibitors are applied in underlying diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and polyarteritis nodosa. The 38 % of patients had received etanercept, 34 % were received with infliximab, whereas the repartition of patients treated with TNF-α inhibitors was 51 % for etanercept, 31 % for infliximab in the whole study population . The most frequent pathogen was Staphylococcus aureus. The pathogen was, in our case, Staphylococcus aureus, which showed the frequent infection secondary to receiving TNF-α inhibitors. The most common sites of secondary infection were bones and joints. Other secondary sites of infections were urinary tract, lungs, digestive tract, dental roots, muscles, and the central nervous system . The cardiac involvement found in our case is very rare.
This case shows the risk of severe bacterial endocarditis from the initiation of TNF-α inhibitor therapy even in a small dose, probably due to drug-induced immunological insufficiency. Physicians should be aware of secondary infections in the application of TNF-α inhibitors, even with proper usage.
Availability of data and materials
SW cared for and treated this patient regarding the dermatological disease. TM, JK, and AF cared for this patient and analyzed the data regarding the cardiac disease. NK and TN held the autopsy as pathologists and revealed macroscopic and microscopic findings. TK critically reviewed the manuscript from the dermatologic and cardiac perspective. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient's next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
This study was conducted with the approval of the ethics committee of Kanazawa Medical University Himi Municipal Hospital, authorization number 32.
The views expressed herein are those of the authors and do not reflect the official policy or position of the Kanazawa Medical University Himi Municipal Hospital, Department of Community Medicine.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Timlin H, Bingham 3rd CO. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. Expert Opin Biol Ther. 2014;14:893–904.View ArticlePubMedGoogle Scholar
- Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74:2107–16.View ArticlePubMedGoogle Scholar
- Loulergue P, Tubach F, Salmon D, Dellamonica P, Taillan B, Thorel JB, et al. Bacteremia in patients receiving TNF-alpha antagonists—a prospective multicenter study. J Infect. 2013;16:524–8.View ArticleGoogle Scholar
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.View ArticlePubMedGoogle Scholar
- Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review. Int J Rheum Dis. 2015. doi:10.1111/1756-185X.12659.PubMedGoogle Scholar
- Ansemant T, Celard M, Tavernier C, Maillefert JF, Delahaye F, et al. Whipple’s disease endocarditis following anti-TNF therapy for atypical rheumatoid arthritis. Joint Bone Spine. 2010;77:622–3.View ArticlePubMedGoogle Scholar
- Kelesidis T, Salhotra A, Fleisher J, Uslan DZ. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect. 2010;60:386–96.View ArticlePubMedGoogle Scholar
- Thomas LH, Arnold C, Fowler Jr VG. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014;312:1330–41.View ArticleGoogle Scholar
- Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011;7:588–98.PubMedGoogle Scholar
- Raychaudhuri SP. A cutting edge overview: psoriatic disease. Clin Rev Allergy Immunol. 2013;44:109–13.View ArticlePubMedGoogle Scholar
- Okoduwa C, Lambert WC, Schwartz RA, Kubeyinje E, Eitokpah A, et al. Erythroderma: review of a potentially life-threatening dermatosis. Indian J Dermatol. 2009;54:1–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxf). 2011;50:124–31.View ArticleGoogle Scholar
- Hoen B, Duval X. Infective Endocarditis. N Engl J Med. 2013;368:1425–33.View ArticlePubMedGoogle Scholar
- Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005;32:2125–9.PubMedGoogle Scholar